

Ibiayi Dagogo-Jack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7555085/publications.pdf>

Version: 2024-02-01

66
papers

5,457
citations

218677

26
h-index

144013

57
g-index

66
all docs

66
docs citations

66
times ranked

8002
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. <i>JCO Precision Oncology</i> , 2022, 6, e2100522. | 3.0 | 8 |
| 2 | Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2022, 40, e21024-e21024. | 1.6 | 0 |
| 3 | Abstract 5172: B cell content in the tumor microenvironment is associated with improved survival in stage II lung adenocarcinoma. <i>Cancer Research</i> , 2022, 82, 5172-5172. | 0.9 | 2 |
| 4 | Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3167-TPS3167. | 1.6 | 4 |
| 5 | Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , . | 3.0 | 10 |
| 6 | Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. <i>Clinical Lung Cancer</i> , 2021, 22, 23-31. | 2.6 | 14 |
| 7 | Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2899-2909. | 7.0 | 62 |
| 8 | Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3152-TPS3152. | 1.6 | 5 |
| 9 | A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859. | 1.1 | 35 |
| 10 | Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype. <i>Journal of Clinical Oncology</i> , 2021, 39, 8555-8555. | 1.6 | 0 |
| 11 | Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion. <i>Oncologist</i> , 2021, 26, 818-824. | 3.7 | 8 |
| 12 | Inserting Ensartinib Into the Starting Lineup for ALK-Rearranged Lung Cancer—A Likely Limited Role on a Deep Bench. <i>JAMA Oncology</i> , 2021, 7, 1615. | 7.1 | 4 |
| 13 | Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 243-243. | 1.6 | 3 |
| 14 | Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954. | 12.8 | 35 |
| 15 | CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49. | 1.2 | 0 |
| 16 | Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 258-265. | 1.1 | 53 |
| 17 | Radiomic features of primary tumor by lung cancer stage: analysis in BRAF mutated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1441-1451. | 2.8 | 9 |
| 18 | Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer. <i>Cancer</i> , 2020, 126, 4473-4484. | 4.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21. | 5.4 | 36 |
| 20 | Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation. <i>Journal of Thoracic Oncology</i> , 2020, 15, e174-e176. | 1.1 | 11 |
| 21 | Clinicopathologic Characteristics of BRG1-Deficient NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 766-776. | 1.1 | 68 |
| 22 | Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. <i>Nature Genetics</i> , 2020, 52, 371-377. | 21.4 | 177 |
| 23 | Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 888-890. | 1.1 | 2 |
| 24 | MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545. | 7.0 | 127 |
| 25 | Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1497-1506. | 1.1 | 46 |
| 26 | A phase II study of lorlatinib in patients (pts) with ALK-positive (ALK+) lung cancer with brain-only progression.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9595-9595. | 1.6 | 5 |
| 27 | Resistance to lorlatinib in <i>ROS1</i> fusion-positive non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9611-9611. | 1.6 | 17 |
| 28 | Reply to the Letter to the Editor From Zhou etÂal. <i>Journal of Thoracic Oncology</i> , 2020, 15, e136-e137. | 1.1 | 0 |
| 29 | The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 2557-2570. | 2.8 | 6 |
| 30 | Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670. | 7.0 | 122 |
| 31 | Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class. <i>Lung Cancer</i> , 2019, 129, 80-84. | 2.0 | 19 |
| 32 | BRAF Mutation Class and Clinical Outcomesâ€”Response. <i>Clinical Cancer Research</i> , 2019, 25, 3189-3189. | 7.0 | 1 |
| 33 | Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History. <i>Journal of Thoracic Oncology</i> , 2019, 14, 835-843. | 1.1 | 9 |
| 34 | Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 816-824. | 1.1 | 78 |
| 35 | GENE-63. GENOMIC CHARACTERIZATION OF HUMAN BRAIN METASTASES IDENTIFIES NOVEL DRIVERS OF LUNG ADENOCARCINOMA PROGRESSION. <i>Neuro-Oncology</i> , 2019, 21, vi111-vi111. | 1.2 | 1 |
| 36 | Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. <i>Journal of Thoracic Oncology</i> , 2019, 14, e226-e228. | 1.1 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 158-165. | 7.0 | 81 |
| 38 | Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 255-264. | 1.1 | 53 |
| 39 | Clinical outcomes of EGFR+ NSCLC pts treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9069-9069. | 1.6 | 1 |
| 40 | Longitudinal analysis of plasma ALK mutations during treatment with next-generation ALK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9068-9068. | 1.6 | 0 |
| 41 | SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. <i>Nature Medicine</i> , 2018, 24, 512-517. | 30.7 | 155 |
| 42 | Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729. | 9.4 | 228 |
| 43 | Tumour heterogeneity and resistance to cancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 81-94. | 27.6 | 2,149 |
| 44 | Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14. | 3.0 | 86 |
| 45 | Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13. | 3.0 | 17 |
| 46 | Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206. | 1.6 | 246 |
| 47 | Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e226-e227. | 1.1 | 43 |
| 48 | Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1530-1538. | 1.1 | 62 |
| 49 | Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. <i>Lung Cancer</i> , 2018, 122, 67-71. | 2.0 | 35 |
| 50 | Long-term efficacy and outcomes with sequential crizotinib followed by alectinib in ALK+ NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9093-9093. | 1.6 | 2 |
| 51 | Clinicopathologic characteristics and molecular features of BRG1-deficient non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12083-12083. | 1.6 | 0 |
| 52 | BRAF-mutant non-small cell lung cancer (NSCLC): Patient (pt) characteristics and outcomes by class of mutation.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9045-9045. | 1.6 | 0 |
| 53 | A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis. <i>Journal of Immunotherapy</i> , 2017, 40, 108-113. | 2.4 | 10 |
| 54 | Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e155-e157. | 1.1 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | The Role of Liquid Biopsies in Lung Cancer Screening. <i>Seminars in Roentgenology</i> , 2017, 52, 185-187. | 0.6 | 2 |
| 56 | Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017, 111, 61-64. | 2.0 | 44 |
| 57 | Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 257-274. | 4.5 | 4 |
| 58 | Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 619-629. | 3.8 | 4 |
| 59 | Expanding the Roster of ROS1 Inhibitors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2595-2597. | 1.6 | 12 |
| 60 | Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i> -Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13. | 3.0 | 158 |
| 61 | Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8536-8536. | 1.6 | 0 |
| 62 | Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?. <i>Oncologist</i> , 2016, 21, 662-663. | 3.7 | 26 |
| 63 | Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1522-1528. | 1.1 | 20 |
| 64 | Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133. | 9.4 | 919 |
| 65 | Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR -Mutant Lung Cancer Harboring De Novo MET Amplification. <i>Journal of Thoracic Oncology</i> , 2016, 11, e83-e85. | 1.1 | 75 |
| 66 | Retrospective analysis of activity of pembrolizumab (pembro) in melanoma patients (pts) with brain metastasis (BM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 2071-2071. | 1.6 | 1 |